Femasys’ (FEMY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research report report published on Thursday, Benzinga reports. The firm currently has a $12.00 target price on the stock.

Separately, Chardan Capital lowered their price target on Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Femasys Stock Up 2.1 %

Shares of FEMY traded up $0.03 during mid-day trading on Thursday, reaching $1.36. 1,033,794 shares of the stock traded hands, compared to its average volume of 338,108. The firm has a market cap of $30.19 million, a price-to-earnings ratio of -1.64 and a beta of -2.82. Femasys has a 12-month low of $0.73 and a 12-month high of $2.40. The company has a quick ratio of 5.93, a current ratio of 6.47 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $1.16 and a 200 day simple moving average of $1.16.

Femasys (NASDAQ:FEMY) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.50 million. Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%. Sell-side analysts expect that Femasys will post -0.79 EPS for the current fiscal year.

Institutional Trading of Femasys

An institutional investor recently raised its position in Femasys stock. CM Management LLC raised its holdings in Femasys Inc. (NASDAQ:FEMY) by 6.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. CM Management LLC owned 1.91% of Femasys worth $484,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.